gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1125Research ArticleГЕПАТОЛОГИЯHEPATOLOGYБезинтерфероновая терапия хронического гепатита С: смена препаратов или новая парадигма лечения?Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?БацкихC. Н.BatskikhS. N.

Бацких Сергей Николаевич – кандидат медицинских наук, научный сотрудник 

111123, Москва, ул. Новогиреевская, д. 3а

Batskikh Sergey N — MD, research associate

111123, Moscow, Novogireyevskaya street, 3а.

zdoc@mail.ruФБУН «Центральный НИИ эпидемиологии» РоспотребнадзораРоссияFederal budget institution of science «Central research institute of epidemiology» of the Federal service on customers' rights protection and human well-being surveillanceRussian Federation2014190420242442331Copyright © Бацких C.Н., 20142014Бацких C.Н.Batskikh S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1125

Цель обзора. Критическая оценка безинтерфероновых схем противовирусной терапии (ПВТ) хронического гепатита С (ХГС) на основании анализа данных клинических исследований.Основные положения. Безинтерфероновые варианты лечения ХГС имеют определенные преимущества над схемами терапии, включающими интерферон-α. Монотерапия препаратами с прямым воздействием на вирус менее эффективна по сравнению с их комбинированным применением. Комбинирование агентов с прямым противовирусным действием значительно снижает риск резистентности, увеличивая вероятность эрадикации вируса. Роль рибавирина при различных безинтерфероновых режимах терапии нуждается в уточнении.Заключение. Новые варианты ПВТ, предусматривающие комбинированное применение препаратов с прямым противовирусным действием (без использования интерферона и рибавирина), позволят существенно упростить схемы, сократить сроки и повысить эффективность лечения у всех категорий пациентов. Такие варианты терапии можно считать новой парадигмой лечения ХГС.

The aim of review

The aim of review. A critical estimation of interferon-free modes of antiviral therapy (AVT) of chronic hepatitis C (CHC) according to the analysis of clinical studies.

Key points

Key points. Interferon-free variants of CHC treatment have certain advantages over modes of interferon-α based treatment. Monotherapy by drugs with direct action on virus is less effective in comparison to combined application. Combination of agents with direct antiviral effect considerably reduces risk of resistance, increasing probability of virus eradication. The role of ribavirin at various interferon-free modes of treatment requires specification.

Conclusion

Conclusion. New variants of the AVT providing combined application of agents with direct antiviral action (without interferon and ribavirin), will allow to simplify algorithms principally, decrease terms and improve efficacy of treatment in all categories of patients. Such variants of therapy can be considered as a new paradigm of CHC treatment.

хронический гепатит Спротивовирусная терапияинтерферон-αрибавиринингибиторы протеазыингибиторы полимеразырезистентность.chronic hepatitis Cantiviral therapyinterferon αribavirinprotease inhibitorspolymerase inhibitorsresistanceReferencesGilead Sciences I. Sofosbuvir [package insert]. 2013. Foster City, CA, Gilead Sciences, Inc.Gilead Sciences I. Sofosbuvir [package insert]. 2013. Foster City, CA, Gilead Sciences, Inc.Janssen Therapeutics. Simeprevir [package insert]. 2013. Titusville, NJ, Janssen Therapeutics.Janssen Therapeutics. Simeprevir [package insert]. 2013. Titusville, NJ, Janssen Therapeutics.Recommendations for Testing, Managing, and Treating Hepatitis C. AASLD. 2014.Recommendations for Testing, Managing, and Treating Hepatitis C. AASLD. 2014.EASL Recommendations on Treatment of Hepatitis C, 2014.EASL Recommendations on Treatment of Hepatitis C, 2014.Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139(1):120-9.Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139(1):120-9.Poordad F., Bronowicki J.P., Gordon S.C., et al. IL28B polymorphism predicts virological response in patients with chronic hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol 2011; 54(suppl 1):6.Poordad F., Bronowicki J.P., Gordon S.C., et al. IL28B polymorphism predicts virological response in patients with chronic hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol 2011; 54(suppl 1):6.Jacobson I.M., Catlett I., Marcellin P., et al. Telaprevir substantially improves SVR rates across all IL28b genotypes in the advanced trial. J Hepatol 2011; 54(suppl 1):542.Jacobson I.M., Catlett I., Marcellin P., et al. Telaprevir substantially improves SVR rates across all IL28b genotypes in the advanced trial. J Hepatol 2011; 54(suppl 1):542.Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13):1195-206.Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13):1195-206.Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13):1207-17.Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13):1207-17.Te H.S., Randall G., Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N-Y). 2007; 3(3):218-25.Te H.S., Randall G., Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N-Y). 2007; 3(3):218-25.Hofmann W.P., Herrmann E., Sarrazin C., Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 2008; 28(10):1332-43.Hofmann W.P., Herrmann E., Sarrazin C., Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 2008; 28(10):1332-43.Farnik H., Zeuzem S. New antiviral therapies in the management of HCV infection. Antivir Ther 2012; 17:77183.Farnik H., Zeuzem S. New antiviral therapies in the management of HCV infection. Antivir Ther 2012; 17:77183.Lalezari J.P., Nelson D.R., Hyland R.H., et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study. J Hepatol 2013; 58:346.Lalezari J.P., Nelson D.R., Hyland R.H., et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study. J Hepatol 2013; 58:346.Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368(1):34-44.Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368(1):34-44.Osinusi A., Meissner E.G., Lee Y.J., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310(8):804-11.Osinusi A., Meissner E.G., Lee Y.J., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310(8):804-11.Barnard R.J., Howe J.A., Ogert R.A., et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013; 444(1-2):329-36.Barnard R.J., Howe J.A., Ogert R.A., et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013; 444(1-2):329-36.Sullivan J.C., de Meyer S., Bartels D.J., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57(2):221-9.Sullivan J.C., de Meyer S., Bartels D.J., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57(2):221-9.Jacobson I., Dore G.J., Foster G.R., et al. Simeprevir (TMC435) with Peginterferon/Ribavirin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58:574.Jacobson I., Dore G.J., Foster G.R., et al. Simeprevir (TMC435) with Peginterferon/Ribavirin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58:574.Poordad F., Manns M.P., Marcellin P., et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. Gastroenterology 2013; 144:151.Poordad F., Manns M.P., Marcellin P., et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. Gastroenterology 2013; 144:151.Forns X., Lawitz E., Zeuzem S., et al. Simeprevir (TMC435) with peg-interferon a-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. Hepatology 2013; 58:737-8.Forns X., Lawitz E., Zeuzem S., et al. Simeprevir (TMC435) with peg-interferon a-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. Hepatology 2013; 58:737-8.Gane E.J., Pockros P., Zeuzem S., et al. Interferonfree treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatmentnaive HCV genotype 1-infected patients. J Hepatol 2012; 56(suppl. 2):555-6.Gane E.J., Pockros P., Zeuzem S., et al. Interferonfree treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatmentnaive HCV genotype 1-infected patients. J Hepatol 2012; 56(suppl. 2):555-6.Poordad F., Lawitz E., Kowdley K.V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368:45-53.Poordad F., Lawitz E., Kowdley K.V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368:45-53.Jensen D., Brunda M., Elston R., Gane E., et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G) 1 treatment-naive patients: interim SVR4 results from the ANNAPURNA study. Hepatology 2013; 58(4):741.Jensen D., Brunda M., Elston R., Gane E., et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G) 1 treatment-naive patients: interim SVR4 results from the ANNAPURNA study. Hepatology 2013; 58(4):741.Volpe J.M., Choe S.S., Reeves J.D., et al. Crosssectional assessment of telaprevir and boceprevir resistanceassociated mutations of 500 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US. Hepatology 2012; 56(suppl. 1):1007.Volpe J.M., Choe S.S., Reeves J.D., et al. Crosssectional assessment of telaprevir and boceprevir resistanceassociated mutations of 500 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US. Hepatology 2012; 56(suppl. 1):1007.Velazquez C., Macartney M.J., Irish D.N., et al. The impact of virologic resistance and adherence on treatment failure in a cohort of hepatitis C virus (HCV) infected patients treated with telaprevir (TVR) and boceprevir (BOC). Hepatology 2012; 56(suppl. 1):716-7.Velazquez C., Macartney M.J., Irish D.N., et al. The impact of virologic resistance and adherence on treatment failure in a cohort of hepatitis C virus (HCV) infected patients treated with telaprevir (TVR) and boceprevir (BOC). Hepatology 2012; 56(suppl. 1):716-7.Kuntzen T., Timm J., Berical A., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatmentnaive patients. Hepatology 2008; 48:1769-78.Kuntzen T., Timm J., Berical A., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatmentnaive patients. Hepatology 2008; 48:1769-78.McCown M.F., Rajyaguru S., Kular S., et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53:2129-32.McCown M.F., Rajyaguru S., Kular S., et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53:2129-32.Lenz O., Fevery B., Verbinnen T., et al. Resistance analyses of HCV isolates from patients treated with simeprevir in phase IIB/III studies. Hepatology 2013; 58:743.Lenz O., Fevery B., Verbinnen T., et al. Resistance analyses of HCV isolates from patients treated with simeprevir in phase IIB/III studies. Hepatology 2013; 58:743.Ferenci P., Asselah T., Foster G.R., et al. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebocontrolled phase III trial. J Gastroenterol Hepatol 2013; 28:157-8.Ferenci P., Asselah T., Foster G.R., et al. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebocontrolled phase III trial. J Gastroenterol Hepatol 2013; 28:157-8.Gao M., Nettles R.E., Belema M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.Gao M., Nettles R.E., Belema M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.Hezode C., Hirschfield G.M., Ghesquiere W., et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results. Hepatology 2012; 56(suppl. 1):553.Hezode C., Hirschfield G.M., Ghesquiere W., et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results. Hepatology 2012; 56(suppl. 1):553.Krishnan P., Beyer J., Koev G., et al. Antiviral activity and resistance profiles for ABT-267, a novel HCV NS5A inhibitor, in vitro and during 3-day monotherapy in HCV genotype-1 (GT1) -infected treatment-naive subjects. Hepatology 2012; 56(suppl. 1):1069.Krishnan P., Beyer J., Koev G., et al. Antiviral activity and resistance profiles for ABT-267, a novel HCV NS5A inhibitor, in vitro and during 3-day monotherapy in HCV genotype-1 (GT1) -infected treatment-naive subjects. Hepatology 2012; 56(suppl. 1):1069.Lawitz E.J., Gruener D., Hill J.M., et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57:24-31.Lawitz E.J., Gruener D., Hill J.M., et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57:24-31.Lagace L., Cartier M., Laflamme G., et al. Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5-days monotherapy. Hepatology 2010; 52(suppl. 1):1205-6.Lagace L., Cartier M., Laflamme G., et al. Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5-days monotherapy. Hepatology 2010; 52(suppl. 1):1205-6.Zeuzem S., Buggisch P., Agarwal K., et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55:749-758.Zeuzem S., Buggisch P., Agarwal K., et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55:749-758.Zhang E.Z., Tigges A., Jiang M., et al. On behalf of the ZENITH Study Group. Characterization of HCV variants in genotype 1 treatment-naive patients administered the combination of TVR and VX-222 in DUAL arms of ZENITH study. J Hepatol 2012; 56(suppl. 2):468-9.Zhang E.Z., Tigges A., Jiang M., et al. On behalf of the ZENITH Study Group. Characterization of HCV variants in genotype 1 treatment-naive patients administered the combination of TVR and VX-222 in DUAL arms of ZENITH study. J Hepatol 2012; 56(suppl. 2):468-9.AbbVie press release 2014 [Accessed 21-03-14].AbbVie press release 2014 [Accessed 21-03-14].Kowdley K.V., Lawitz E., Poordad F., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-32.Kowdley K.V., Lawitz E., Poordad F., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-32.Supplementary Appendix to: Kowdley K.V., Lawitz E., Poordad F., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-32.Supplementary Appendix to: Kowdley K.V., Lawitz E., Poordad F., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-32.Ferenci P., Bernstein D., Lalezari J., et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med DOI:10.1056/NEJMoa1402338.Ferenci P., Bernstein D., Lalezari J., et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med DOI:10.1056/NEJMoa1402338.Lawitz E., Hezode C., Varunok P., et al. Interferonand Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naive Patients and Prior Null Responders. Hepatology 2013; 58:244.Lawitz E., Hezode C., Varunok P., et al. Interferonand Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naive Patients and Prior Null Responders. Hepatology 2013; 58:244.Lawitz E. Interferonand ribavirin-free regimen of ABT450/r + ABT-267 in HCV genotype 1b-infected treatmentnaive patients and prior null responders. Oral presentation. American Association for the Study of Liver Diseases: The liver meeting 2013, Nov 1-5, 2013; Washington, DC.Lawitz E. Interferonand ribavirin-free regimen of ABT450/r + ABT-267 in HCV genotype 1b-infected treatmentnaive patients and prior null responders. Oral presentation. American Association for the Study of Liver Diseases: The liver meeting 2013, Nov 1-5, 2013; Washington, DC.

The authors declare that there are no conflicts of interest present.